GAAP net loss for the first quarter of 2026 was $8.3 million, compared to $426.1 million for the first quarter of 2025. Non-GAAP net loss for the first quarter of 2026 was $35.9 million, compared to ...
StockStory.org on MSN
PacBio (NASDAQ:PACB) misses Q1 CY2026 sales expectations
Genomics company Pacific Biosciences of California (NASDAQ:PACB) in Q1 CY2026, with sales flat year on year at $37.18 million ...
PacBio (PACB) stock drops 16% after a Q1 revenue miss and margin pressure; full-year 2026 revenue guidance narrowed below estimates.
The HiFi Solves Sub-fertility Consortium in Asia Pacific was launched at PRISM Asia 2024 to advance long-read sequencing in reproductive genomics. Its first major findings will now be presented at ...
Q1 2026 Management view "Our first quarter of 2026 was highlighted by record consumable revenue, greater than 100% year-over-year growth in consumable shipments to clinically focused accounts and ...
PacBio beats Q1 earnings estimates as consumables growth and cost cuts offset flat revenue and a weaker gross margin.
Detailed price information for Pacific Biosciences (PACB-Q) from The Globe and Mail including charting and trades.
Detailed price information for Pacific Biosciences (PACB-Q) from The Globe and Mail including charting and trades.
HiFi Long-Read Sequencing Panel Supports Comprehensive Analysis of 20 Genes Associated With Neurological Disease MENLO PARK, Calif., March 12, 2024 /PRNewswire/ -- PacBio (PACB) (NASDAQ: PACB), a ...
Revenue guidance for 2026 was narrowed at the high end to $165 million to $175 million, assuming consumables remain the ...
Pacific Biosciences of California shares fell after the company posted first-quarter revenue below Wall Street estimates. Shares of the biotechnology company fell 15% on Friday to $1.41. The company's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results